噻托溴铵联合沙美特罗氟替卡松治疗慢性阻塞性肺疾病稳定期的疗效分析

目的观察噻托溴铵联合沙美特罗氟替卡松50/500对Ⅲ-Ⅳ级慢性阻塞性肺疾病稳定期（COPD）的治疗效果。方法随机将87例Ⅲ-Ⅳ级COPD稳定期病患者分为观察组（45例）和对照组（42例）。观察组吸入噻托溴铵及沙美特罗氟替卡松50/500,对照组吸入沙美特罗氟替卡松50/500。分别对两组患者治疗前、治疗后3、6、9、12个月进行COPDAssessment Test（CAT）,肺功能检测和累计患者出现急性加重次数。结果两组的肺功能、CAT评分均有改善,观察组改善更为显著,急性加重次数减少,两组比较差异有统计学意义（P〈0.05）。结论治疗Ⅲ-Ⅳ级COPD稳定期的病患者,沙美特罗氟替卡松50/500或联合噻托溴铵均可以持续改善病患者的症状及肺功能,减少急性加重的风险,但联合用药效果更好。

Analysis of the Treatment of Stable Chronic Obstructive Pulmonary Diseas with Tiotropium Bromide Combined Salmeterol Fluticasone

Objective To investigate the effects of Tiotropium bromide combined Salmeterol Fluticasone50/500 for the treatment in patients with stable COPD in Ⅲ-Ⅳdegrees.Methods Eighty-seven patients were randomly divided into the observation group of 45 cases and the control group of 42 cases.The observation group was given Tiotropium bromide combined with Salmeterol Fluticasone50/500,the control group was only given Salmeterol Fluticasone50/500.The COPD Assessment Test （CAT） and pulmonary function of two groups were examined and compared respectively at baseline,3,6,9 and 12 monthes after treatment,as well as recorded the frequency of AECOPD.Results The CAT and pulmonary function of two groups were all improved,but the improvement was much greater and the frequency of AECOPD reduced in the observation group than that in the control group. There was significant difference （P0.05）.Conclusion Salmeterol Fluticasone50/500 single or combined with Tiotropium bromide all cna improve symptoms,pulmonary function of patients with stable COPD in Ⅲ-Ⅳdegrees,and reduce the danger to become AECOPD. These were continuous.But it is further advance efficacy using both together.